<DOC>
	<DOCNO>NCT01924533</DOCNO>
	<brief_summary>This study phase III , multi-centre study olaparib combination paclitaxel , compare placebo combination paclitaxel patient advance gastric cancer progress follow first-line therapy . Patients China , Japan , Korea Taiwan .</brief_summary>
	<brief_title>Efficacy Safety Study Olaparib Combination With Paclitaxel Treat Advanced Gastric Cancer .</brief_title>
	<detailed_description>A randomized , double-blinded , multicentre phase III study access efficacy safety olaparib combination paclitaxel , compare placebo combination paclitaxel Asian patient advance gastric cancer ( include gastro-oesophageal junction ) progress follow first line therapy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Advanced gastric cancer ( include GEJ ) progress follow firstline therapy . Patients must ≥18 year age . Age ≥20 Japanese Provision tumour sample ( either resection biopsy ) . At least one lesion ( measurable and/or nonmeasurable ) accurately assess imaging ( CT/MRI ) baseline follow visit . More one prior chemotherapy regimen ( except adjuvant/neoadjuvant chemotherapy 6 month wash period ) treatment gastric cancer advance set . Any previous treatment Polyadenosine 5'diphosphoribose [ poly ( ADPribose ) ] polymerisation ( PARP ) inhibitor , include olaparib . Patients second primary cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour curatively treat evidence disease ≥5 year . Human Epidermalgrowth Factor Receptor2 ( HER2 ) positive patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>